Abstract

Research Article

Elderly (> 70 years) Multiple Myeloma Patients Benefit Equally from Autologous Hematopoietic Stem Cell Transplantation When Compared to Younger Patients

Nicholas Prabhakar, Sheila Haugh, Leonard Klein, Tulio Rodriguez and Jacob Bitran*

Published: 08 August, 2024 | Volume 8 - Issue 1 | Pages: 042.047

Autologous Hematopoietic Stem Cell Transplantation (AHSCT) performed after induction therapy is the standard of care for newly diagnosed Multiple Myeloma (MM) patients who qualify. Our institution has performed AHSCT for MM since 1991, and in this study, we sought to retrospectively examine the outcomes of 303 MM patients who underwent AHSCT from 1991-2021. We focused on Overall Survival (OS) and Progression-Free Survival (PFS) in patients in addition to Landmark survival (1-year post-transplantation). We found that in elderly patients > 70 years of age there was no significant difference in OS at 12 years, with 51% for patients < 70 years of age and 50% > 70; these were the same numbers for PFS at 12 years as well. We also found that median overall survival is improving overall with each decade in our transplanted MM patients with patient survival improved to over > 80% regardless of age at 7 years, when the previous median overall survival was 6 - 6.6 years before 2001. Given our findings, supported by others, we show that survival is continually improving over time in MM AHSCT patients and that AHSCT can be performed safely with equivalent landmark and long-term PFS and OS in patients of advanced age.

Read Full Article HTML DOI: 10.29328/journal.jsctt.1001042 Cite this Article Read Full Article PDF

Keywords:

Multiple myeloma; Autologous stem cell transplantation; Long-term transplant survival; Advanced age patients

References

  1. Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008 Mar 15;111(6):2962-2972. Available from: https://doi.org/10.1182/blood-2007-10-078022
  2. Alwall N. Urethane and stilbamidine in multiple myeloma: Report on two cases. Lancet. 1947;2(6472):388. Available from: https://doi.org/10.1016/s0140-6736(47)90375-9
  3. Blokhin N, Larionov L, Perevodchikova N, Chebotareva L, Merkulova N. Annals of the New York Academy of Sciences. 1958;68(3):1128-1132. Available from: https://doi.org/10.1111/j.1749-6632.1958.tb42675.x
  4. Mass RE. A comparison of the effect of prednisone and a placebo in the treatment of multiple myeloma. Cancer Chemother Rep. 1962;16:257-259. Available from: https://pubmed.ncbi.nlm.nih.gov/14470881/
  5. Osgood EE. The survival time of patients with plasmocytic myeloma. Cancer Chemother Rep. 1960;9:1-10. Available from: https://pubmed.ncbi.nlm.nih.gov/13731417/
  6. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999 Nov 18;341(21):1565-1571. Available from: https://doi.org/10.1056/nejm199911183412102
  7. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003 Jun 26;348(26):2609-2617. Available from: https://doi.org/10.1056/nejmoa030288
  8. Osserman EF, DiRe LB, DiRe J, Sherman WH, Hersman JA, Storb R. Identical twin marrow transplantation in multiple myeloma. Acta Haematol. 1982;68(3):215-223. Available from: https://doi.org/10.1159/000206984
  9. Barlogie B, Alexanian R, Dicke KA, Zagars G, Spitzer G, Jagannath S, Horwitz L. High dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood. 1987 Sep;70(3):869-872. Available from: https://pubmed.ncbi.nlm.nih.gov/3304465/
  10. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996;335(2):91-97. Available from: https://doi.org/10.1056/nejm199607113350204
  11. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003 Mar 27;348(13):1875-1883. Available from: https://doi.org/10.1056/nejmoa022340
  12. Lehners N, Becker N, Benner A, Pritsch M, Löpprich M, Mai EK, et al. Analysis of long-term survival in multiple myeloma after first-line autologous stem cell transplantation: impact of clinical risk factors and sustained response. Cancer Med. 2018;7(2):307-316. Available from: https://doi.org/10.1002/cam4.1283
  13. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008 Mar 1;111(5):2516-2520. Available from: https://doi.org/10.1182/blood-2007-10-116129
  14. Nishimura KK, Barlogie B, van Rhee F, Zangari M, Walker BA, Rosenthal A, et al. Long-term outcomes after autologous stem cell transplantation for multiple myeloma. Blood Adv. 2020;4(2):422-431. Available from: https://doi.org/10.1182/bloodadvances.2019000524
  15. Schaapveld M, Visser O, Siesling S, Schaar CG, Zweegman S, Vellenga E. Improved survival among younger but not among older patients with multiple myeloma in the Netherlands, a population-based study since 1989. Eur J Cancer. 2010;46(1):160-169. Available from: https://doi.org/10.1016/j.ejca.2009.07.006
  16. Oliver-Caldes A, Soler-Perromat JC, Lozano E, Moreno D, Bataller A, Mozas P, et al. Long-term responders after autologous stem cell transplantation in multiple myeloma. Front Oncol. 2022;12:936993. Available from: https://doi.org/10.3389/fonc.2022.936993
  17. Pasvolsky O, Wang Z, Milton DR, Tanner MR, Bashir Q, Srour S, et al. Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation. Blood Cancer J. 2024;14(1):82. Available from: https://doi.org/10.1038/s41408-024-01062-2
  18. Paquin A, Visram A, Kumar SK, Gertz MA, Cantwell H, Buadi FK, et al. Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma. Blood Cancer J. 2020;10:87. Available from: https://doi.org/10.1038/s41408-020-00353-8
  19. Munshi PN, Vesole D, Jurczyszyn A, Zaucha JM, St Martin A, Davila O, et al. Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. Cancer. 2020 Dec 1;126(23):5077-5087. Available from: https://doi.org/10.1002/cncr.33171
  20. Sharma M, Zhang MJ, Zhong X, Abidi MH, Akpek G, Bacher U, et al. Older patients with myeloma derive similar benefit from autologous transplantation. Biol Blood Marrow Transplant. 2014;20(11):1796-1803. Available from: https://doi.org/10.1016/j.bbmt.2014.07.013
  21. El Cheikh J, Kfoury E, Calmels B, Lemarie C, Stoppa AM, Bouabdallah R, et al. Age at transplantation and outcome after autologous stem cell transplantation in elderly patients with multiple myeloma. Hematol Oncol Stem Cell Ther. 2011;4(1):30-36. Available from: https://doi.org/10.5144/1658-3876.2011.30
  22. Kumar SK, Dingli D, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, et al. Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis. Am J Hematol. 2008 Aug;83(8):614-617. Available from: https://doi.org/10.1002/ajh.21191
  23. Bashir Q, Shah N, Parmar S, Wei W, Rondon G, Weber DM, et al. Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma. Leuk Lymphoma. 2012;53(1):118-22. Available from: https://doi.org/10.3109/10428194.2011.606942
  24. Qazilbash MH, Saliba RM, Hosing C, Mendoza F, Qureshi SR, Weber DM, et al. Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. Bone Marrow Transplant. 2007;39(5):279-283. Available from: https://doi.org/10.1038/sj.bmt.1705580
  25. Ludmir EB, Mainwaring W, Lin TA, Miller AB, Jethanandani A, Espinoza AF, et al. Factors associated with age disparities among cancer clinical trial participants. JAMA Oncol. 2019;5(12):1769-1773. Available from: https://doi.org/10.1001/jamaoncol.2019.2055
  26. Stadtmauer EA, Pasquini MC, Blackwell B, Hari P, Bashey A, Devine S, et al. Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: Results of the BMT CTN 0702 trial. J Clin Oncol. 2019;37(7):589-597. Available from: https://doi.org/10.1200/jco.18.00685
  27. Gehan EA. A generalized Wilcoxon test for comparing arbitrarily single-censored samples. Biometrika. 1965;52(3-4):203-224. Available from: https://doi.org/10.2307/2333825
  28. Anderson KC, Alsina M, Bensinger W, Biermann JS, Cohen AD, Devine S, et al. Multiple myeloma, version 1.2013. J Natl Compr Canc Netw. 2013;11(1):11-17. Available from: https://doi.org/10.6004/jnccn.2013.0004
  29. Dhakal B, Nelson A, Guru Murthy GS, Fraser R, Eastwood D, Hamadani M, et al. Autologous hematopoietic cell transplantation in patients with multiple myeloma: Effect of age. Clin Lymphoma Myeloma Leuk. 2017;17(3):165-172. Available from: https://doi.org/10.1016/j.clml.2016.11.006
  30. Sirohi B, Powles R, Treleaven J, Mainwaring P, Kulkarni S, Pandha H, et al. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transplant. 2000 May;25(5):533-539. Available from: https://doi.org/10.1038/sj.bmt.1702188
  31. Chari A, Palumbo A, Mateos MV, et al. Daratumumab plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Patients with Multiple Myeloma (NDMM): Final Analysis of Griffin Among Clinically Relevant Subgroups. Blood. 2022;140(Supplement 1):7278-7281. Available from: https://ashpublications.org/blood/article/140/12/1345/485817/Diagnosis-and-management-of-AML-in-adults-2022

Figures:

Similar Articles

  • The outcome of autologous hematopoietic stem cell transplantation in patients with multiple myeloma. The experience of King Fahad Specialist Hospital in Dammam, Saudi Arabia
    Khalid Ahmed Al-Anazi*, Mutahar E, Abduljalil O, Kanfer S, Kaloyannidis P, Estanislao A, Apostolidis I, Almokhtar N, Darweesh M, Abdulbaqi M, Alenazi W, Alshammasi Z, Alshaibani Z, Kawarie M, Raslan H, Albahrani A, Alsaber A, AlMulhem N, Dridi W, Aldayel A, Alrabeh R, Alshami A, Ayyad A, Abu Rahma F, Lardizabal J, Salam A, Haque K, Alsagheir A and Alhashmi H Khalid Ahmed Al-Anazi*,Mutahar E,Abduljalil O,Kanfer S,Kaloyannidis P,Estanislao A,Apostolidis I,Almokhtar N,Darweesh M,Abdulbaqi M,Alenazi W,Alshammasi Z,Alshaibani Z,Kawarie M,Raslan H,Albahrani A,Alsaber A,AlMulhem N,Dridi W,Aldayel A,Alrabeh R,Alshami A,Ayyad A,Abu Rahma F,Lardizabal J,Salam A,Haque K,Alsagheir A,Alhashmi H. The outcome of autologous hematopoietic stem cell transplantation in patients with multiple myeloma. The experience of King Fahad Specialist Hospital in Dammam, Saudi Arabia. . 2022 doi: 10.29328/journal.jsctt.1001027; 6: 019-028
  • Outcome of Outpatient Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma and Relapsed and Refractory Hodgkin Lymphoma. The Experience of King Fahad Specialist Hospital in Dammam, Saudi Arabia
    Khalid Ahmed Al-Anazi*, Alshami A, Mutahar E, Abduljalil O, Kanfer S, Kaloyannidis P, Bacal J, Estanislao A, Apostolidis I, Almokhtar N, Darweesh M, Abdulbaqi M, Alenazi W, Alshammasi Z, Albanyan O, Ayyad A, Alsomali Z, Albatran M, Raslan H, Albahrani A, Alsaber A, AlMulhem N, Dridi W, Alrabeh R, Abu Rahma F, Nightingale F, Ahadai P and Alhashmi H Khalid Ahmed Al-Anazi*,Alshami A,Mutahar E,Abduljalil O,Kanfer S,Kaloyannidis P,Bacal J,Estanislao A,Apostolidis I,Almokhtar N,Darweesh M,Abdulbaqi M,Alenazi W,Alshammasi Z,Albanyan O,Ayyad A,Alsomali Z,Albatran M,Raslan H,Albahrani A,Alsaber A,AlMulhem N,Dridi W,Alrabeh R,Abu Rahma F,Nightingale F,Ahadai P,Alhashmi H. Outcome of Outpatient Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma and Relapsed and Refractory Hodgkin Lymphoma. The Experience of King Fahad Specialist Hospital in Dammam, Saudi Arabia. . 2023 doi: 10.29328/journal.jsctt.1001030; 7: 003-015
  • Elderly (> 70 years) Multiple Myeloma Patients Benefit Equally from Autologous Hematopoietic Stem Cell Transplantation When Compared to Younger Patients
    Nicholas Prabhakar, Sheila Haugh, Leonard Klein, Tulio Rodriguez and Jacob Bitran* Nicholas Prabhakar, Sheila Haugh, Leonard Klein, Tulio Rodriguez, Jacob Bitran*. Elderly (> 70 years) Multiple Myeloma Patients Benefit Equally from Autologous Hematopoietic Stem Cell Transplantation When Compared to Younger Patients. . 2024 doi: 10.29328/journal.jsctt.1001042; 8: 042.047

Recently Viewed

Read More

Most Viewed

Read More

Help ?